Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation

Review proposal consultation

Stakeholder matrix (PDF 263 KB)

Multiple myeloma (induction therapy) -bortezomib: equality impact assessment -guidance review 

Multiple myeloma - bortezomib (induction therapy): final appraisal determination information

Multiple myeloma - bortezomib (induction therapy): FAD document

Multiple myeloma - bortezomib (induction therapy): FAD document (PDF 428 KB)

Multiple myeloma - bortezomib (induction therapy): evaluation report information

Multiple myeloma - bortezomib (induction therapy): appraisal consultation

Multiple myeloma - bortezomib (induction therapy): appraisal consultation document information

Multiple myeloma - bortezomib (induction therapy): evaluation report information

Multiple myeloma - bortezomib (induction therapy): appendix D - response to consultee and commentator comments on the draft scope and provisional matrix 

Multiple myeloma - bortezomib (induction therapy): final scope

Multiple myeloma - bortezomib (induction therapy): final matrix

Multiple myeloma - bortezomib (induction therapy): EIA scoping

Multiple myeloma - bortezomib (induction therapy): appendix B - draft scope for consultation (pre-referral) - November 2011 

Multiple myeloma - bortezomib (induction therapy): Appendix C - provisional matrix (pre-referral) - November 2011